www.fdanews.com/articles/157306-transition-in-new-licensing-deal-with-eli-lilly

Transition in New Licensing Deal with Eli Lilly

July 24, 2013

Canadian Transition Therapeutics has made a deal with Eli Lilly to license the latter’s TT-601 small molecule transcription regulator to treat osteoarthritis pain.
The Pharma Letter